

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

01 Jul 2026

### Comparison of the effect of OABM WITH OABF regimens in In the treatment of Helicobacter pylori patients

#### Protocol summary

##### Study aim

: Comparison of the effect of OABM WITH OABF regimens in In the treatment of Helicobacter pylori patients referred to Mofateh Clinic1 of Yasuj University of Medical Sciences in 2022-2023

##### Design

Phase 3 clinical trial in two parallel groups receiving the regimen ABF(omeprazole\_furazolidone\_bismuth subcitrate\_ amoxicillin) and OABM(omeprazole\_metronidazole\_bismuth subcitrate\_ amoxicillin), single blind, randomized using a table of numbers

##### Settings and conduct

This study will be conducted in the field of Helicobacter pylori infection treatment in Yasouj University of Medical Sciences in Fatah 1 Clinic. The study is performed on patients with personal consent. Patients will receive ABF or OABM drug in two groups randomly. The researchers were blinded to the type of intervention assigned to the patients.

##### Participants/Inclusion and exclusion criteria

Patients with dyspepsia, without indication for endoscopy, with a positive Helicobacter diagnostic test, including Helicobacter stool antigen test

##### Intervention groups

In one group, omeprazole 20 mg twice a day (Bid) is continued for two weeks with antibiotics and then for 6 weeks without antibiotics, and after 4 weeks of this treatment period, the patient gives a stool antigen test to check the eradication of Helicobacter pylori. Amoxicillin 1 gram twice a day, bismuth citrate tablets twice a day and furazolidone 200 mg twice a day (Bid), in the other group omeprazole 20 mg twice a day along with antibiotics for 2 weeks and then for 6 weeks without antibiotics and alone and after this 6-week period, the patient will refer to stool antigen test method 4 weeks later without taking drugs and antibiotics for eradication test. In this group, amoxicillin one gram twice in day and two tablets of bismuth citrate twice a day (4 tablets a

day) and metronidazole 500 mg twice a day

##### Main outcome variables

Helicobacter pylori antigen negativity

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20150622022869N11**

Registration date: **2023-06-11, 1402/03/21**

Registration timing: **prospective**

Last update: **2023-06-11, 1402/03/21**

Update count: **0**

##### Registration date

2023-06-11, 1402/03/21

##### Registrant information

##### Name

Moslem Sedaghattalab

##### Name of organization / entity

Yasuj University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 74 3322 0163

##### Email address

m.sedaghattalab@yums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2023-06-20, 1402/03/30

##### Expected recruitment end date

2023-07-01, 1402/04/10

##### Actual recruitment start date

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Comparison of the effect of OABM WITH OABF regimens in In the treatment of Helicobacter pylori patients

**Public title**

Comparison of the effect of OABM WITH OABF regimens in In the treatment of Helicobacter pylori patients

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

A patient who underwent endoscopy and has peptic ulcer disease (PUD). Patients with dyspepsia without endoscopic indication have a positive Helicobacter diagnostic test, including Helicobacter stool antigen test and.... Patients with maltoma Endoscopy patients with nud (non-ulcer dyspepsia) and patients with a history of cancer in their first degree relatives will be included in the study. Patients who have a history of pud and are Helicobacter positive and are taking NSAID Treatment-resistant dyspepsia Patient satisfaction

**Exclusion criteria:**

Previous history of H pylori treatment Allergy to antibiotics Allergy to PPI History of gastrectomy Having gastric cancer pregnant women Taking antibiotics in the last month Taking PPI or h2blocker in the last two weeks Chronic liver, kidney or lung disease History of Fauvism

**Age**

From **18 years** old to **80 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Care provider
- Investigator
- Outcome assessor
- Data analyser

**Sample size**

Target sample size: **70**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Random number table method is used for randomization in this study. In this method, random table is used for randomization and patients are assigned random numbers from the table. Patients in each of the two study groups will be assigned to one of the two groups based on random numbers.

**Blinding (investigator's opinion)**

Single blinded

**Blinding description**

The present study will be single blind, in which the researchers of this study will be blinded to the type of intervention assigned to the patients.

**Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Yasuj University of Medical Sciences

**Street address**

Dr. Jalil St., campus of Yasouj University of Medical Sciences., Yasuj., Iran

**City**

Yasuj

**Province**

Kohgilouyeh-va-Boyerahmad

**Postal code**

7591994799

**Approval date**

2023-01-03, 1401/10/13

**Ethics committee reference number**

IR.YUMS.REC.1401.159

**Health conditions studied****1****Description of health condition studied**

helicobacter pylori (h. pylori) infection

**ICD-10 code**

B96.81

**ICD-10 code description**

Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

**Primary outcomes****1****Description**

Frequency distribution of Helicobacter pylori antigen negativity

**Timepoint**

12weeks after the start of the study

**Method of measurement**

Stool antigen test

**2****Description**

Drug side effects

**Timepoint**

12 weeks

**Method of measurement**

Clinical examination and patient presentation

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

First intervention group: omeprazole 20 mg twice a day (Bid) is continued for two weeks with antibiotics and then for 6 weeks without antibiotics, and after 4 weeks of this treatment period, the patient gives a stool antigen test to check the eradication of *Helicobacter pylori*.

Amoxicillin 1 gram twice a day, bismuth citrate tablets twice a day and furazolidone 200 mg twice a day (Bid)

#### Category

Treatment - Drugs

### 2

#### Description

Second intervention group: omeprazole 20 mg twice a day along with antibiotics for 2 weeks and then for 6 weeks without antibiotics and alone and then this 6-week period, the patient will refer to stool antigen test method 4 weeks later without taking drugs and antibiotics for eradication test. In this group, amoxicillin one gram twice in day and two tablets of bismuth citrate twice a day (4 tablets a day) and metronidazole 500 mg twice a day

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Shahid Muftah Clinic

##### Full name of responsible person

Moslem Sedaghattalab

##### Street address

Dr. Jalil St., campus of Yasouj University of Medical Sciences., Yasuj

##### City

Yasuj

##### Province

Kohgiluyeh-va-Boyerahmad

##### Postal code

7591994799

##### Phone

+98 74 3334 5876

##### Email

m.sedaghattalab@yums.ac.com

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Yasouj University of Medical Sciences

##### Full name of responsible person

Seyed Amin Hossaini Motlagh

##### Street address

Dr. Jalil St., campus of Yasouj University of Medical Sciences., Yasuj

##### City

Yasuj

##### Province

Kohgiluyeh-va-Boyerahmad

##### Postal code

7591994799

##### Phone

+98 74 3334 5876

##### Email

aminhomo@yahoo.com

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Yasouj University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Yasouj University of Medical Sciences

##### Full name of responsible person

Moslem Sedaghattalab

##### Position

Consultant

##### Latest degree

Medical doctor

##### Other areas of specialty/work

Internal Medicine

##### Street address

Dr. Jalil St., campus of Yasouj University of Medical Sciences., Yasuj

##### City

Yasuj

##### Province

Kohgiluyeh-va-Boyerahmad

##### Postal code

7591994799

##### Phone

+98 74 3334 5876

**Email**  
m.sedaghattalab@yuma.ac.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Yasouj University of Medical Sciences

**Full name of responsible person**  
Moslem Sedaghttalab

**Position**  
Consultant

**Latest degree**  
Medical doctor

**Other areas of specialty/work**  
Internal Medicine

**Street address**  
Dr. Jalil St., campus of Yasouj University of Medical Sciences,. Yasuj

**City**  
Yasuj

**Province**  
Kohgilouyeh-va-Boyrahmad

**Postal code**  
7591994799

**Phone**  
+98 74 3334 5876

**Email**  
m.sedaghattalab@yuma.ac.com

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Yasouj University of Medical Sciences

**Full name of responsible person**  
Moslem Sedaghttalab

**Position**  
Consultant

**Latest degree**  
Medical doctor

**Other areas of specialty/work**  
Internal Medicine

**Street address**  
Dr. Jalil St., campus of Yasouj University of Medical Sciences,. Yasuj

**City**  
Yasuj

**Province**  
Kohgilouyeh-va-Boyrahmad

**Postal code**  
7591994799

**Phone**  
+98 74 3334 5876

**Email**  
m.sedaghattalab@yuma.ac.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

### Study Protocol

Yes - There is a plan to make this available

### Statistical Analysis Plan

Yes - There is a plan to make this available

### Informed Consent Form

Yes - There is a plan to make this available

### Clinical Study Report

Yes - There is a plan to make this available

### Analytic Code

Yes - There is a plan to make this available

### Data Dictionary

Yes - There is a plan to make this available

### Title and more details about the data/document

The data of this study can be shared without mentioning individuals and in aggregate form after the publication of the article through administrative correspondence.

### When the data will become available and for how long

After printing the article

### To whom data/document is available

this is available for people working in academic institutions or people working in businesses can also apply to receive it.

### Under which criteria data/document could be used

Any analysis on the data will be allowed

### From where data/document is obtainable

m.sedaghattalab@yuma.ac.com

### What processes are involved for a request to access data/document

After sending the email, the required data will be available for up to 1 month

### Comments